Market revenue in 2023 | USD 531.3 million |
Market revenue in 2030 | USD 855.6 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.59% in 2023. Horizon Databook has segmented the Canada inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
In November 2022, USD 1 million grant was provided by the Canadian Inflammatory Bowel Disease Research Consortium for increasing clinical research in the country to improve quality of life of IBD patients.
Canada-based companies, such as Giiant Pharma, Inc., are being provided USD 500,000 by the U.S. Crohn’s and Colitis Foundation for developing GT-2108 for severe and moderate ulcerative colitis. The most commonly used biologics in the country are Humira and Remicade. This provides boost to international players such as AbbVie and Janssen Biotech, Inc.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Canada inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account